Skip to main content
Top

Open Access 29-01-2025 | IL-23 Inhibitor | Original Research Article

Interleukin-23 versus Interleukin-17 Inhibitors in Preventing Incidental Psoriatic Arthritis in Patients with Psoriasis: A Real-World Comparison From the TriNetX US Collaborative Network

Authors: Sebastian Yu, An-Ping Huo, Yu-Hsun Wang, James Cheng-Chung Wei

Published in: BioDrugs

Login to get access

Abstract

Background

Psoriatic arthritis (PsA) is a common comorbidity in patients with psoriasis (PsO) that leads to significant disease burden. Biologic therapies targeting the interleukin (IL)-23/IL-17 axis have been widely used for PsO, but their comparative effectiveness in preventing PsA remains unclear.

Objective

The study objective was to compare the occurrence of developing incidental PsA among PsO patients treated with interleukin-23 inhibitors (IL23is) or interleukin-17 inhibitors (IL17is).

Methods

A retrospective cohort study was conducted using real-world data from the TriNetX US Collaborative Network, including 53 healthcare organizations. Adult PsO patients treated with IL23is or IL17is between January 2019 and June 2022 were identified. Cox regression analysis was used to assess the risk of PsA incidence, with hazard ratios (HRs) and 95% confidence intervals (CIs) reported. Subgroup analyses were performed based on age, sex, and ethnicity. Sensitivity analyses included comparisons with tumor necrosis factor (TNF) inhibitors (TNFis) to ensure robustness.

Results

A total of 4,580 PsO patients were included in the study, with 2,273 receiving IL23is and 2,307 receiving IL17is. Treatment with IL23is was associated with a significantly lower incidence of PsA compared to IL17is (HR = 0.60, 95% CI 0.44–0.82, P = 0.001). This reduction in risk was particularly notable in the 41- to 65-year age group (HR = 0.42, 95% CI 0.27–0.64, P < 0.001) and among females (HR = 0.57, 95% CI 0.38–0.86, P = 0.007). Subgroup analyses based on ethnicity revealed varying outcomes, with White patients showing a significant risk reduction (HR = 0.55, 95% CI 0.38–0.79, P = 0.001) but no significant risk reduction was observed in Black or African American patients (HR = 1.37, 95% CI 0.37–5.13, P = 0.637). Sensitivity analyses comparing IL23is and TNFis confirmed the robustness of the findings.

Conclusion

IL23is are associated with a lower risk of PsA incidence compared to IL17is in PsO patients, particularly in specific age, sex, and ethnic groups. These findings suggest that IL23is may be more suitable for PsO patients at high risk of PsA and could inform potential updates to treatment guidelines. Further research should focus on refining therapeutic strategies by incorporating patient-specific factors such as comorbidities, ethnicity, and genetic predispositions, which could optimize biologic selection and enhance PsA prevention efforts in clinical practice.
Appendix
Available only for authorised users
Literature
1.
go back to reference Tran MM, Moseley IH, George EA, Qureshi AA, Cho E. Examining the burden of psoriasis and psoriatic arthritis in a US adult cohort using the All of Us Research Program. J Am Acad Dermatol. 2023;89(4):859–62.PubMedPubMedCentralCrossRef Tran MM, Moseley IH, George EA, Qureshi AA, Cho E. Examining the burden of psoriasis and psoriatic arthritis in a US adult cohort using the All of Us Research Program. J Am Acad Dermatol. 2023;89(4):859–62.PubMedPubMedCentralCrossRef
2.
go back to reference Zhang L, Wang Y, Qiu L, Wu J. Psoriasis and cardiovascular disease risk in European and East Asian populations: evidence from meta-analysis and Mendelian randomization analysis. Bmc Med. 2022;20(1):421.PubMedPubMedCentralCrossRef Zhang L, Wang Y, Qiu L, Wu J. Psoriasis and cardiovascular disease risk in European and East Asian populations: evidence from meta-analysis and Mendelian randomization analysis. Bmc Med. 2022;20(1):421.PubMedPubMedCentralCrossRef
3.
4.
go back to reference Wu JJ, Kavanaugh A, Lebwohl MG, Gniadecki R, Merola JF. Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2022;36(6):797–806.PubMedPubMedCentralCrossRef Wu JJ, Kavanaugh A, Lebwohl MG, Gniadecki R, Merola JF. Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2022;36(6):797–806.PubMedPubMedCentralCrossRef
5.
go back to reference Yang S-F, Chen T-H, Tsai S-H, Chen P-E, Chi C-C, Tung T-H. Risk of chronic kidney disease and end-stage renal disease in patients with psoriasis: a systematic review and meta-analysis of cohort studies. Dermatol Sin. 2021;39(1):19.CrossRef Yang S-F, Chen T-H, Tsai S-H, Chen P-E, Chi C-C, Tung T-H. Risk of chronic kidney disease and end-stage renal disease in patients with psoriasis: a systematic review and meta-analysis of cohort studies. Dermatol Sin. 2021;39(1):19.CrossRef
6.
go back to reference Ungprasert P, Raksasuk S. Psoriasis and risk of incident chronic kidney disease and end-stage renal disease: a systematic review and meta-analysis. Int Urol Nephrol. 2018;50(7):1277–83.PubMedCrossRef Ungprasert P, Raksasuk S. Psoriasis and risk of incident chronic kidney disease and end-stage renal disease: a systematic review and meta-analysis. Int Urol Nephrol. 2018;50(7):1277–83.PubMedCrossRef
7.
go back to reference Chu M, Shen S, Zhu Z, Li Z, Bai Y, Ma J, et al. Association of psoriasis with depression, anxiety, and suicidality: a bidirectional two-sample Mendelian randomization study. J Dermatol. 2023;50(12):1629–34.PubMedCrossRef Chu M, Shen S, Zhu Z, Li Z, Bai Y, Ma J, et al. Association of psoriasis with depression, anxiety, and suicidality: a bidirectional two-sample Mendelian randomization study. J Dermatol. 2023;50(12):1629–34.PubMedCrossRef
8.
go back to reference Yu S, Yu CL, Huang YC, Tu HP, Lan CE. Risk of developing psoriasis in patients with schizophrenia: a nationwide retrospective cohort study. J Eur Acad Dermatol Venereol. 2017;31(9):1497–504.PubMedCrossRef Yu S, Yu CL, Huang YC, Tu HP, Lan CE. Risk of developing psoriasis in patients with schizophrenia: a nationwide retrospective cohort study. J Eur Acad Dermatol Venereol. 2017;31(9):1497–504.PubMedCrossRef
9.
go back to reference Tu H-P, Yu C-L, Lan C-CE, Yu S. Prevalence of schizophrenia in patients with psoriasis: a nationwide study. Dermatol Sin. 2017;35(1):1–6.CrossRef Tu H-P, Yu C-L, Lan C-CE, Yu S. Prevalence of schizophrenia in patients with psoriasis: a nationwide study. Dermatol Sin. 2017;35(1):1–6.CrossRef
10.
go back to reference AlQassimi S, AlBrashdi S, Galadari H, Hashim MJ. Global burden of psoriasis–comparison of regional and global epidemiology, 1990 to 2017. Int J Dermatol. 2020;59(5):566–71.PubMedCrossRef AlQassimi S, AlBrashdi S, Galadari H, Hashim MJ. Global burden of psoriasis–comparison of regional and global epidemiology, 1990 to 2017. Int J Dermatol. 2020;59(5):566–71.PubMedCrossRef
11.
go back to reference Wu JJ, Suryavanshi M, Davidson D, Patel V, Jain A, Seigel L. Economic burden of comorbidities in patients with psoriasis in the USA. Dermatol Ther (Heidelb). 2023;13(1):207–19.PubMedCrossRef Wu JJ, Suryavanshi M, Davidson D, Patel V, Jain A, Seigel L. Economic burden of comorbidities in patients with psoriasis in the USA. Dermatol Ther (Heidelb). 2023;13(1):207–19.PubMedCrossRef
12.
go back to reference Nguyen HT, Vu AT, Pham NTU, Tran TNA, Pham NN, Bui HTT, et al. Comorbidity burden and treatment patterns of psoriasis in vietnam: real-world data from the EXPAND Study. Dermatol Ther (Heidelb). 2023;13(12):3193–208.PubMedPubMedCentralCrossRef Nguyen HT, Vu AT, Pham NTU, Tran TNA, Pham NN, Bui HTT, et al. Comorbidity burden and treatment patterns of psoriasis in vietnam: real-world data from the EXPAND Study. Dermatol Ther (Heidelb). 2023;13(12):3193–208.PubMedPubMedCentralCrossRef
13.
go back to reference Feldman SR, Zhao Y, Shi L, Tran MH. Economic and comorbidity burden among patients with moderate-to-severe psoriasis. J Manag Care Spec Pharm. 2015;21(10):874–88.PubMed Feldman SR, Zhao Y, Shi L, Tran MH. Economic and comorbidity burden among patients with moderate-to-severe psoriasis. J Manag Care Spec Pharm. 2015;21(10):874–88.PubMed
14.
go back to reference Feldman SR, Zhao Y, Shi L, Tran MH, Lu J. Economic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis. Arthritis Care Res (Hoboken). 2015;67(5):708–17.PubMedPubMedCentralCrossRef Feldman SR, Zhao Y, Shi L, Tran MH, Lu J. Economic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis. Arthritis Care Res (Hoboken). 2015;67(5):708–17.PubMedPubMedCentralCrossRef
15.
go back to reference Yu S, Wei JC. Regarding Mastorino et al.’s “Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients.” J Eur Acad Dermatol Venereol. 2023;37(12):e1388–9.PubMedCrossRef Yu S, Wei JC. Regarding Mastorino et al.’s “Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients.” J Eur Acad Dermatol Venereol. 2023;37(12):e1388–9.PubMedCrossRef
16.
go back to reference Blauvelt A, Pariser DM, Tyring S, Bagel J, Alexis AF, Soung J, et al. Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study. J Dermatol Sci. 2023;109(1):12–21.PubMedCrossRef Blauvelt A, Pariser DM, Tyring S, Bagel J, Alexis AF, Soung J, et al. Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study. J Dermatol Sci. 2023;109(1):12–21.PubMedCrossRef
17.
go back to reference Vacharanukrauh P, Meephansan J, Ponnikorn S, Tangtanatakul P, Soonthornchai W, Wongpiyabovorn J, et al. Transcriptome profiling in psoriasis: NB-UVB treatment-associated transcriptional changes and modulation of autoinflammation in perilesional skin in early-phase disease. J Dermatol Sci. 2022;107(3):123–32.PubMedCrossRef Vacharanukrauh P, Meephansan J, Ponnikorn S, Tangtanatakul P, Soonthornchai W, Wongpiyabovorn J, et al. Transcriptome profiling in psoriasis: NB-UVB treatment-associated transcriptional changes and modulation of autoinflammation in perilesional skin in early-phase disease. J Dermatol Sci. 2022;107(3):123–32.PubMedCrossRef
19.
go back to reference Reich K, Armstrong AW, Langley RG, Flavin S, Randazzo B, Li S, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831–9.PubMedCrossRef Reich K, Armstrong AW, Langley RG, Flavin S, Randazzo B, Li S, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831–9.PubMedCrossRef
20.
go back to reference Mastorino L, Susca S, Cariti C, Sliquini N, Verrone A, Stroppiana E, et al. Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients. J Eur Acad Dermatol Venereol. 2023;37(9):1848–53.PubMedCrossRef Mastorino L, Susca S, Cariti C, Sliquini N, Verrone A, Stroppiana E, et al. Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients. J Eur Acad Dermatol Venereol. 2023;37(9):1848–53.PubMedCrossRef
21.
go back to reference Gisondi P, Bellinato F, Targher G, Idolazzi L, Girolomoni G. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Ann Rheum Dis. 2022;81(1):68–73.PubMedCrossRef Gisondi P, Bellinato F, Targher G, Idolazzi L, Girolomoni G. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Ann Rheum Dis. 2022;81(1):68–73.PubMedCrossRef
22.
go back to reference Watad A, Zabotti A, Patt YS, Gendelman O, Dotan A, Ben-Shabat N, et al. From psoriasis to psoriatic arthritis: decoding the impact of treatment modalities on the prevention of psoriatic arthritis. Rheumatol Ther. 2024;11(4):963–76.PubMedPubMedCentralCrossRef Watad A, Zabotti A, Patt YS, Gendelman O, Dotan A, Ben-Shabat N, et al. From psoriasis to psoriatic arthritis: decoding the impact of treatment modalities on the prevention of psoriatic arthritis. Rheumatol Ther. 2024;11(4):963–76.PubMedPubMedCentralCrossRef
23.
go back to reference Zabotti A, De Marco G, Gossec L, Baraliakos X, Aletaha D, Iagnocco A, et al. EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis. Ann Rheum Dis. 2023;82(9):1162–70.PubMedCrossRef Zabotti A, De Marco G, Gossec L, Baraliakos X, Aletaha D, Iagnocco A, et al. EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis. Ann Rheum Dis. 2023;82(9):1162–70.PubMedCrossRef
24.
go back to reference De Marco G, Zabotti A, Baraliakos X, Iagnocco A, Aletaha D, Gisondi P, et al. Characterisation of prodromal and very early psoriatic arthritis: a systematic literature review informing a EULAR taskforce. RMD Open. 2023;9(2): e003143.PubMedPubMedCentralCrossRef De Marco G, Zabotti A, Baraliakos X, Iagnocco A, Aletaha D, Gisondi P, et al. Characterisation of prodromal and very early psoriatic arthritis: a systematic literature review informing a EULAR taskforce. RMD Open. 2023;9(2): e003143.PubMedPubMedCentralCrossRef
25.
go back to reference Huang X, Shentu H, He Y, Lai H, Xu C, Chen M, et al. Efficacy and safety of IL-23 inhibitors in the treatment of psoriatic arthritis: a meta-analysis based on randomized controlled trials. Immunol Res. 2023;71(4):505–15.PubMedPubMedCentralCrossRef Huang X, Shentu H, He Y, Lai H, Xu C, Chen M, et al. Efficacy and safety of IL-23 inhibitors in the treatment of psoriatic arthritis: a meta-analysis based on randomized controlled trials. Immunol Res. 2023;71(4):505–15.PubMedPubMedCentralCrossRef
26.
go back to reference Haberman RH, MacFarlane KA, Catron S, Samuels J, Blank RB, Toprover M, et al. Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial. BMJ Open. 2022;12(12): e063650.PubMedPubMedCentralCrossRef Haberman RH, MacFarlane KA, Catron S, Samuels J, Blank RB, Toprover M, et al. Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial. BMJ Open. 2022;12(12): e063650.PubMedPubMedCentralCrossRef
27.
go back to reference Ak T, Temiz SNY, Taner M, Ayla AY, Aygun AA, Engin B, et al. Effectiveness of anti-interleukin-23 therapy in psoriatic arthritis: a pilot prospective real-world study. Int J Rheum Dis. 2023;26(5):878–84.PubMedCrossRef Ak T, Temiz SNY, Taner M, Ayla AY, Aygun AA, Engin B, et al. Effectiveness of anti-interleukin-23 therapy in psoriatic arthritis: a pilot prospective real-world study. Int J Rheum Dis. 2023;26(5):878–84.PubMedCrossRef
28.
go back to reference Caldarola G, De Luca E, Bavetta M, Bernardini N, Dattola A, De Simone C, et al. 2-Year experience with risankizumab in the treatment of plaque psoriasis in Lazio region, Italy. Dermatol Ther. 2023;19:2023. Caldarola G, De Luca E, Bavetta M, Bernardini N, Dattola A, De Simone C, et al. 2-Year experience with risankizumab in the treatment of plaque psoriasis in Lazio region, Italy. Dermatol Ther. 2023;19:2023.
29.
go back to reference Singla S, Putman M, Liew J, Gordon K. Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study. Lancet Rheumatol. 2023;5(4):e200–7.PubMedCrossRef Singla S, Putman M, Liew J, Gordon K. Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study. Lancet Rheumatol. 2023;5(4):e200–7.PubMedCrossRef
30.
go back to reference Yen FS, Wang SI, Hsu CC, Hwu CM, Wei JC. Sodium-glucose cotransporter-2 inhibitors and nephritis among patients with systemic lupus erythematosus. JAMA Netw Open. 2024;7(6): e2416578.PubMedPubMedCentralCrossRef Yen FS, Wang SI, Hsu CC, Hwu CM, Wei JC. Sodium-glucose cotransporter-2 inhibitors and nephritis among patients with systemic lupus erythematosus. JAMA Netw Open. 2024;7(6): e2416578.PubMedPubMedCentralCrossRef
31.
go back to reference Wang WJ, Wang YH, Huang CH, Hsieh TH, Ibarburu GH, Wei JCC. Paxlovid use is associated with lower risk of cardiovascular diseases in COVID-19 patients with autoimmune rheumatic diseases: a retrospective cohort study. Bmc Med. 2024;22(1):117.PubMedPubMedCentralCrossRef Wang WJ, Wang YH, Huang CH, Hsieh TH, Ibarburu GH, Wei JCC. Paxlovid use is associated with lower risk of cardiovascular diseases in COVID-19 patients with autoimmune rheumatic diseases: a retrospective cohort study. Bmc Med. 2024;22(1):117.PubMedPubMedCentralCrossRef
32.
go back to reference Tsai RY, Gau SY, Ho YJ, Lin SY, Ku CY, Wang SI, et al. Long-COVID impacts taste and olfactory in individuals with substance use disorder: a retrospective cohort study from the TriNetX US Collaborative Networks. Psychiatry Res. 2024;337: 115970.PubMedCrossRef Tsai RY, Gau SY, Ho YJ, Lin SY, Ku CY, Wang SI, et al. Long-COVID impacts taste and olfactory in individuals with substance use disorder: a retrospective cohort study from the TriNetX US Collaborative Networks. Psychiatry Res. 2024;337: 115970.PubMedCrossRef
33.
go back to reference Loo YP, Loo CH, Lim AL, Wong CK, Ali NBM, Khor YH, et al. Prevalence and risk factors associated with psoriatic arthritis among patients with psoriasis. Int J Rheum Dis. 2023;26(9):1788–98.PubMedCrossRef Loo YP, Loo CH, Lim AL, Wong CK, Ali NBM, Khor YH, et al. Prevalence and risk factors associated with psoriatic arthritis among patients with psoriasis. Int J Rheum Dis. 2023;26(9):1788–98.PubMedCrossRef
34.
go back to reference Fragoulis GE, Siebert S. The role of IL-23 and the use of IL-23 inhibitors in psoriatic arthritis. Musculoskeletal Care. 2022 Nov;20 Suppl 1(Suppl 1):S12-S21. Fragoulis GE, Siebert S. The role of IL-23 and the use of IL-23 inhibitors in psoriatic arthritis. Musculoskeletal Care. 2022 Nov;20 Suppl 1(Suppl 1):S12-S21.
35.
go back to reference Yu S, Lee CW, Li YA, Chen TH, HS Y. Prenatal infection predisposes offspring to enhanced susceptibility to imiquimod-mediated psoriasiform dermatitis in mice. Dermatol Sin. 2022;40(1):14-9. Yu S, Lee CW, Li YA, Chen TH, HS Y. Prenatal infection predisposes offspring to enhanced susceptibility to imiquimod-mediated psoriasiform dermatitis in mice. Dermatol Sin. 2022;40(1):14-9.
36.
go back to reference Chiricozzi A, Coscarella G, Puig L, Vender R, Yeung J, Carrascosa JM, et al. Age affects drug survival rates of interleukin (IL)-17 and IL-23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi-country, cohort study. J Eur Acad Dermatol Venereol. 2024;38(11):2175–85.PubMedCrossRef Chiricozzi A, Coscarella G, Puig L, Vender R, Yeung J, Carrascosa JM, et al. Age affects drug survival rates of interleukin (IL)-17 and IL-23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi-country, cohort study. J Eur Acad Dermatol Venereol. 2024;38(11):2175–85.PubMedCrossRef
37.
go back to reference Chen L, Deshpande M, Grisotto M, Smaldini P, Garcia R, He Z, et al. Skin expression of IL-23 drives the development of psoriasis and psoriatic arthritis in mice. Sci Rep. 2020;10(1):8259.PubMedPubMedCentralCrossRef Chen L, Deshpande M, Grisotto M, Smaldini P, Garcia R, He Z, et al. Skin expression of IL-23 drives the development of psoriasis and psoriatic arthritis in mice. Sci Rep. 2020;10(1):8259.PubMedPubMedCentralCrossRef
38.
go back to reference McGonagle DG, Zabotti A, Watad A, Bridgewood C, De Marco G, Kerschbaumer A, et al. Intercepting psoriatic arthritis in patients with psoriasis: buy one get one free? Ann Rheum Dis. 2022;81(1):7–10.PubMedCrossRef McGonagle DG, Zabotti A, Watad A, Bridgewood C, De Marco G, Kerschbaumer A, et al. Intercepting psoriatic arthritis in patients with psoriasis: buy one get one free? Ann Rheum Dis. 2022;81(1):7–10.PubMedCrossRef
39.
go back to reference Cai R, Jin Y, Chen B, Zhao J, Zhai J, Zeng L, et al. Impact of targeted therapies on the risk of cardiovascular events in patients with psoriasis and psoriatic arthritis: a systematic review and aggregate data meta-analysis of randomized controlled trials. Int J Rheum Dis. 2023;26(4):625–37.PubMedCrossRef Cai R, Jin Y, Chen B, Zhao J, Zhai J, Zeng L, et al. Impact of targeted therapies on the risk of cardiovascular events in patients with psoriasis and psoriatic arthritis: a systematic review and aggregate data meta-analysis of randomized controlled trials. Int J Rheum Dis. 2023;26(4):625–37.PubMedCrossRef
40.
41.
go back to reference Wertheimer T, Zwicky P, Rindlisbacher L, Sparano C, Vermeer M, de Melo BMS, et al. IL-23 stabilizes an effector T(reg) cell program in the tumor microenvironment. Nat Immunol. 2024;25(3):512–24.PubMedPubMedCentralCrossRef Wertheimer T, Zwicky P, Rindlisbacher L, Sparano C, Vermeer M, de Melo BMS, et al. IL-23 stabilizes an effector T(reg) cell program in the tumor microenvironment. Nat Immunol. 2024;25(3):512–24.PubMedPubMedCentralCrossRef
42.
go back to reference Jacobse J, Pilat JM, Li J, Brown RE, Kwag A, Buendia MA, et al. Distinct roles for interleukin-23 receptor signaling in regulatory T cells in sporadic and inflammation-associated carcinogenesis. Front Oncol. 2023;13:1276743.PubMedCrossRef Jacobse J, Pilat JM, Li J, Brown RE, Kwag A, Buendia MA, et al. Distinct roles for interleukin-23 receptor signaling in regulatory T cells in sporadic and inflammation-associated carcinogenesis. Front Oncol. 2023;13:1276743.PubMedCrossRef
43.
go back to reference Mehta H, Mashiko S, Angsana J, Rubio M, Hsieh YM, Maari C, et al. Differential changes in inflammatory mononuclear phagocyte and t-cell profiles within psoriatic skin during treatment with guselkumab vs. secukinumab. J Invest Dermatol. 2021;141(7):1707–18.PubMedCrossRef Mehta H, Mashiko S, Angsana J, Rubio M, Hsieh YM, Maari C, et al. Differential changes in inflammatory mononuclear phagocyte and t-cell profiles within psoriatic skin during treatment with guselkumab vs. secukinumab. J Invest Dermatol. 2021;141(7):1707–18.PubMedCrossRef
44.
go back to reference Leijten EF, van Kempen TS, Olde Nordkamp MA, Pouw JN, Kleinrensink NJ, Vincken NL, et al. Tissue-resident memory CD8+ T cells from skin differentiate psoriatic arthritis from psoriasis. Arthritis Rheumatol. 2021;73(7):1220–32.PubMedPubMedCentralCrossRef Leijten EF, van Kempen TS, Olde Nordkamp MA, Pouw JN, Kleinrensink NJ, Vincken NL, et al. Tissue-resident memory CD8+ T cells from skin differentiate psoriatic arthritis from psoriasis. Arthritis Rheumatol. 2021;73(7):1220–32.PubMedPubMedCentralCrossRef
45.
go back to reference Torres T, Puig L, Vender R, Yeung J, Carrascosa JM, Piaserico S, et al. Drug survival of interleukin (IL)-17 and IL-23 inhibitors for the treatment of psoriasis: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2022;23(6):891–904.PubMedCrossRef Torres T, Puig L, Vender R, Yeung J, Carrascosa JM, Piaserico S, et al. Drug survival of interleukin (IL)-17 and IL-23 inhibitors for the treatment of psoriasis: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2022;23(6):891–904.PubMedCrossRef
46.
47.
go back to reference Yang SF, Lin MH, Chou PC, Hu SK, Shih SY, Yu HS, et al. Genetics of generalized pustular psoriasis: current understanding and implications for future therapeutics. Genes (Basel). 2023;14(6):1297.PubMedPubMedCentralCrossRef Yang SF, Lin MH, Chou PC, Hu SK, Shih SY, Yu HS, et al. Genetics of generalized pustular psoriasis: current understanding and implications for future therapeutics. Genes (Basel). 2023;14(6):1297.PubMedPubMedCentralCrossRef
48.
go back to reference Yu S, Tsao YH, Tu HP, CCE L. Drug survival of biologic agents in patients with psoriatic arthritis from a medical center in southern Taiwan. Dermatol Sin. 2022;40(1):20-7. Yu S, Tsao YH, Tu HP, CCE L. Drug survival of biologic agents in patients with psoriatic arthritis from a medical center in southern Taiwan. Dermatol Sin. 2022;40(1):20-7.
49.
go back to reference Mastorino L, Ortoncelli M, Dapavo P, Ribero S, Quaglino P. Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients’-response to Yu et al. J Eur Acad Dermatol Venereol. 2024;38(2):e175–6.PubMedCrossRef Mastorino L, Ortoncelli M, Dapavo P, Ribero S, Quaglino P. Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients’-response to Yu et al. J Eur Acad Dermatol Venereol. 2024;38(2):e175–6.PubMedCrossRef
50.
go back to reference Gershater B, Bieber K, Vorobyev A, Ludwig MA, Zirpel H, De Luca DA, et al. Differential risks of psoriatic arthritis development in patients with varied psoriasis manifestations: a sex- and ethnicity-specific analysis. Front Med (Lausanne). 2024;11:1385491.PubMedPubMedCentralCrossRef Gershater B, Bieber K, Vorobyev A, Ludwig MA, Zirpel H, De Luca DA, et al. Differential risks of psoriatic arthritis development in patients with varied psoriasis manifestations: a sex- and ethnicity-specific analysis. Front Med (Lausanne). 2024;11:1385491.PubMedPubMedCentralCrossRef
51.
go back to reference Lu C, Yang F, Liu H, Dou L, Wang Y, Li H, et al. Chinese Registry of Psoriatic Arthritis (CREPAR): I. Clinical characteristics of Chinese patients with psoriatic arthritis. Int J Rheum Dis. 2023;26(9):1737–44.PubMedCrossRef Lu C, Yang F, Liu H, Dou L, Wang Y, Li H, et al. Chinese Registry of Psoriatic Arthritis (CREPAR): I. Clinical characteristics of Chinese patients with psoriatic arthritis. Int J Rheum Dis. 2023;26(9):1737–44.PubMedCrossRef
52.
go back to reference Takeshita J, Chau J, Duffin KC, Goel N. Promoting diversity, equity, and inclusion for psoriatic diseases. J Rheumatol. 2022;49(6 Suppl 1):48–51.PubMed Takeshita J, Chau J, Duffin KC, Goel N. Promoting diversity, equity, and inclusion for psoriatic diseases. J Rheumatol. 2022;49(6 Suppl 1):48–51.PubMed
53.
go back to reference Yadav G, Yeung J, Miller-Monthrope Y, Lakhani O, Drudge C, Craigie S, et al. Unmet need in people with psoriasis and skin of color in Canada and the United States. Dermatol Ther (Heidelb). 2022;12(11):2401–13.PubMedPubMedCentralCrossRef Yadav G, Yeung J, Miller-Monthrope Y, Lakhani O, Drudge C, Craigie S, et al. Unmet need in people with psoriasis and skin of color in Canada and the United States. Dermatol Ther (Heidelb). 2022;12(11):2401–13.PubMedPubMedCentralCrossRef
54.
go back to reference McKenzie S, Brown-Korsah JB, Syder NC, Omar D, Taylor SC, Elbuluk N. Variations in genetics, biology, and phenotype of cutaneous disorders in skin of color Part II: Differences in clinical presentation and disparities in cutaneous disorders in skin of color. J Am Acad Dermatol. 2022;87(6):1261–70.PubMedCrossRef McKenzie S, Brown-Korsah JB, Syder NC, Omar D, Taylor SC, Elbuluk N. Variations in genetics, biology, and phenotype of cutaneous disorders in skin of color Part II: Differences in clinical presentation and disparities in cutaneous disorders in skin of color. J Am Acad Dermatol. 2022;87(6):1261–70.PubMedCrossRef
55.
go back to reference Peterson H, Huang MY, Lee K, Kingston P, Yee D, Korouri E, et al. Comorbidity burden in psoriasis patients with skin of color. J Psoriasis Psoriatic Arthritis. 2024;9(1):16–22.PubMedCrossRef Peterson H, Huang MY, Lee K, Kingston P, Yee D, Korouri E, et al. Comorbidity burden in psoriasis patients with skin of color. J Psoriasis Psoriatic Arthritis. 2024;9(1):16–22.PubMedCrossRef
56.
go back to reference Zabotti A, Fagni F, Gossec L, Giovannini I, Sticherling M, Tullio A, et al. Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: exploring the subclinical psoriatic arthritis stage. RMD Open. 2024;10(2): e004314.PubMedPubMedCentralCrossRef Zabotti A, Fagni F, Gossec L, Giovannini I, Sticherling M, Tullio A, et al. Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: exploring the subclinical psoriatic arthritis stage. RMD Open. 2024;10(2): e004314.PubMedPubMedCentralCrossRef
57.
go back to reference Errichetti E, Zabotti A. Biologics in prevention of psoriasis to psoriatic arthritis transition: the need of prospective analyses and stratification according to time-related risk factors. Dermatol Ther (Heidelb). 2024;14(1):1–3.PubMedCrossRef Errichetti E, Zabotti A. Biologics in prevention of psoriasis to psoriatic arthritis transition: the need of prospective analyses and stratification according to time-related risk factors. Dermatol Ther (Heidelb). 2024;14(1):1–3.PubMedCrossRef
58.
go back to reference Floris A, Mugheddu C, Sichi L, Anedda J, Frau A, Sorgia J, et al. Treatment of psoriasis with different classes of biologics reduces the likelihood of peripheral and axial psoriatic arthritis development. Rheumatology (Oxford). 2024; p. keae257 (ahead of print). Floris A, Mugheddu C, Sichi L, Anedda J, Frau A, Sorgia J, et al. Treatment of psoriasis with different classes of biologics reduces the likelihood of peripheral and axial psoriatic arthritis development. Rheumatology (Oxford). 2024; p. keae257 (ahead of print).
59.
go back to reference Ozince RB, Ak T, Erzin YZ, Melikoglu M, Seyahi E. Secukinumab-induced IgA vasculitis in a patient with psoriatic arthritis. Int J Rheum Dis. 2023;26(9):1811–5.PubMedCrossRef Ozince RB, Ak T, Erzin YZ, Melikoglu M, Seyahi E. Secukinumab-induced IgA vasculitis in a patient with psoriatic arthritis. Int J Rheum Dis. 2023;26(9):1811–5.PubMedCrossRef
Metadata
Title
Interleukin-23 versus Interleukin-17 Inhibitors in Preventing Incidental Psoriatic Arthritis in Patients with Psoriasis: A Real-World Comparison From the TriNetX US Collaborative Network
Authors
Sebastian Yu
An-Ping Huo
Yu-Hsun Wang
James Cheng-Chung Wei
Publication date
29-01-2025
Publisher
Springer International Publishing
Published in
BioDrugs
Print ISSN: 1173-8804
Electronic ISSN: 1179-190X
DOI
https://doi.org/10.1007/s40259-025-00705-5